On May 11, 2023 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, reported that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) (Free EHA Whitepaper) 2023 Hybrid Congress and the 17TH International Conference on Malignant Lymphoma (17-ICML) (Press release, Nkarta, MAY 11, 2023, View Source [SID1234631527]). NKX019 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target the B-cell antigen CD19.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The purpose of the presentations is to ensure that clinical investigators and the broader clinical community have the opportunity to assess the NKX019 clinical data from the November 2022 data cut-off in a peer-reviewed format. These data were previously disclosed at a company event in December 2022. Nkarta continues to plan to present an update to these data later in 2023.
European Hematology Association 2023 Hybrid Congress
Oral Presentation: First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/Refractory (R/R) B-Cell Malignancies
June 10, 2023
Session s437 4:30 p.m. – 5:45 p.m. CEST
Presentation S261
Abstracts are available on the EHA (Free EHA Whitepaper) website.
17TH International Conference on Malignant Lymphoma
Encore Poster Presentation: First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/Refractory (R/R) B-Cell Malignancies
June 14 – June 16, 2023
Abstract 389
Abstract titles are available on the 17-ICML website.
Abstracts are expected to be available on the ICML website on June 9, 2023 at 5:59 p.m. ET.
The presentations will be made available electronically on the Nkarta website following their delivery at the scheduled scientific sessions.
About NKX019
NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors. It is engineered with a humanized CD19-directed CAR for enhanced tumor cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal and malignant B cells, and it is a validated target for B cell cancer therapies. To learn more about the NKX019 clinical trial in adults with advanced B cell malignancies, please visit ClinicalTrials.gov.